The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Severe Depression, Suicide Attempts, and Ideation During the Use of Interferon Beta by Patients With Multiple Sclerosis
Abstract
BACKGROUND: Interferon (IFN) beta is a safe and efficient drug for treating multiple sclerosis (MS). It is widely accepted that previously depressed patients may get worse when using IFN-beta. There are few reports on the association of IFN-beta and severe depression among patients without previous psychiatric history. METHODS: Discussion of a case of a patient with MS who developed severe depression and attempted suicide while using IFN-beta encouraged us to review the subject. A group of neurologists in Brazil retrospectively gathered together their similar cases for the present paper. RESULTS: The present paper reports on 11 cases of severe depression with suicide attempts or ideation among patients with MS who were using IFN-beta. These patients had no previous history of any psychiatric disease. Nine patients developed the symptoms over a relatively short period (4 months, on average). Two patients developed severe depression after more than 1 year of treatment with IFN-beta. Phobic, aggressive, behavioral, psychotic, and manic symptoms also were observed in these patients, thus suggesting the existence of a complex mood-behavior disorder associated with this drug. Interferon beta withdrawal led to complete remission of symptoms. The Naranjo algorithm established a highly probable association between IFN-beta and this adverse reaction in these patients. CONCLUSIONS: Although uncommon, severe depression with suicide ideation or attempts may be observed during treatment of MS with IFN-beta. This association should not discourage the use of this drug, but physicians need to be aware of this possible adverse event from IFN-beta.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and in patients receiving pro-inflammatory cytokines for the treatment of multiple sclerosis.[19]”
From SUICIDAL IDEATION IS ASSOCIATED WITH ELEVATED INFLAMMATION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: Research Article: Suicidal Ideation and Inflammation (2013) · cites this paper as [19]
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483
Multiple sclerosis beyond EDSS: depression and fatigue.
Ziemssen, T. (2009) · Journal of Neurological Sciences · doi:10.1016/s0022-510x(09)70011-5 · Cited by 168
Interferon in relapsing-remitting multiple sclerosis
Rice, G. P., Incorvaia, B., Munari, L., Ebers, G. C., Polman, C. H., D’Amico, R., Parmelli, E., & Filippini, G. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002002 · Cited by 146
Neuropsychiatric disorders related to interferon and interleukins treatment
Myint, A. M., Schwarz, M. J., Steinbusch, H. W. M., & Leonard, B. E. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9114-5 · Cited by 116
Multiple Sclerosis, interferon beta-1b and depression
Feinstein, A., O’Connor, P., & Feinstein, K. (2002) · Journal of Neurology · doi:10.1007/s00415-002-0725-0 · Cited by 103
Psychiatric side effects of interferon-β in multiple sclerosis
Goëb, J.-L., EVEN, C., Nicolas, G., Gohier, B., Dubas, F., & Garré, J.-B. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2005.09.013 · Cited by 96
Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study
Fermo, S. L., Barone, R. M. E., Patti, F., Laisa, P., Cavallaro, T. L., Nicoletti, A. S. Q., & Zappia, M. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510365157 · Cited by 79
Major depression during interferon-α treatment: vulnerability and prevention
Lotrich, F. E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.4/felotrich · Cited by 72
Course of Depression During the Initiation of Interferon Beta-1a Treatment for Multiple Sclerosis
Mohr, D. C., Likosky, W., Dwyer, P., Wende, J. V. D., Boudewyn, A. C., & Goodkin, D. (1999) · Archives of Neurology · doi:10.1001/archneur.56.10.1263 · Cited by 68
Interferon-β1afor the treatment of multiple sclerosis
Clerico, M., Contessa, G., & Durelli, L. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.4.535 · Cited by 64
Managing Depression during Hepatitis C Treatment
Sockalingam, S., & Abbey, S. E. (2009) · The Canadian Journal of Psychiatry · doi:10.1177/070674370905400906 · Cited by 60
Erim, Y., Tagay, S., Beckmann, M., Bein, S., Cicinnati, V., Beckebaum, S., Senf, W., & Schlaak, J. F. (2010) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2009.08.002 · Cited by 48
Assessing the Role of Drugs in Suicidal Ideation and Suicidality
Reith, D. M., & Edmonds, L. K. (2007) · CNS Drugs · doi:10.2165/00023210-200721060-00003 · Cited by 45
Goëb, J.-L., Cailleau, A., Lainé, P., Etcharry‐Bouyx, F., Maugin, D., Duverger, P., Gohier, B., Rannou-Dubas, K., Dubas, F., & Garré, J.-B. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200301000-00002 · Cited by 41
Long-term emotional state of multiple sclerosis patients treated with interferon beta
Porcel, J., Río, J., Sánchez-Betancourt, A., Arévalo, M. J., Tintoré, M., Téllez, N., Borrás, C., Nos, C., & Montalbán, X. (2006) · Multiple Sclerosis Journal · doi:10.1177/1352458506070748 · Cited by 30
Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis
Lana–Peixoto, M. A., Teixeira, A. L., & Haase, V. G. (2002) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2002000500007 · Cited by 29
High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis
Hartung, H. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802677882 · Cited by 21
Psychiatric disorders in multiple sclerosis patients
Fazzito, M. M., Jordy, S. S., & Tilbery, C. P. (2009) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2009000400017 · Cited by 21
Carroll, W. M. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458509105426 · Cited by 18
Dépression et sclérose en plaques
Lebrun‐Frénay, C., & Cohen, M. (2009) · Revue Neurologique · doi:10.1016/s0035-3787(09)72128-9 · Cited by 18
Boyко, A. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003702361 · Cited by 11
Research works printed but not linked: 1
- Naranjo, 1981, Empirical delineation of the probability spectrum of adverse drug reactions., Clin Pharmacol Ther, 29, 267
Cited by
Sorted by citations
Connecting inflammation with glutamate agonism in suicidality
Erhardt, S., Lim, C. K., Linderholm, K. R., Janelidze, S., Lindqvist, D., Samuelsson, M., Lundberg, K., Postolache, T. T., Träskman-Bendz, L., Guillemin, G. J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.248 · Cited by 345
Toward a Biosignature for Suicide
Oquendo, M. A., Sullivan, G. M., Sudol, K., Baca-Garcia, E., Stanley, B. H., Sublette, M. E., & Mann, J. J. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14020194 · Cited by 299
Bay-Richter, C., Linderholm, K. R., Lim, C. K., Samuelsson, M., Träskman-Bendz, L., Guillemin, G. J., Erhardt, S., & Brundin, L. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.07.012 · Cited by 304
Role of Inflammation in Suicide: From Mechanisms to Treatment
Brundin, L., Bryleva, E. Y., & Thirtamara Rajamani, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.116 · Cited by 257
“In a subset of MS patients with no history of psychiatric illness, treatment with IFN-γ worsens depressive symptoms and induces suicidal ideation or attempts (Benros et al , 2011; Chwastiak et al , 2002; Fragoso et al , 2010).”
Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder
Sublette, M. E., Galfalvy, H. C., Fuchs, D., Lapidus, M., Grunebaum, M. F., Oquendo, M. A., John Mann, J., & Postolache, T. T. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.05.002 · Cited by 250
Metadata
- Authors
- Fragoso, Y. D., Frota, E. R. C., Lopes, J. S., Noal, J. S., Giacomo, M. C., Gomes, S., Gonçalves, M. V. M., da Gama, P. D., & Finkelsztejn, A.
- Affiliations
- Beneficência Portuguesa de São Paulo (BR)
- Hospital de Clínicas de Porto Alegre (BR)
- Corresponding author
- Finkelsztejn, Alessandro
- Venue
- Clinical Neuropharmacology
- Published
- 2010-11
- Volume
- 33
- Issue
- 6
- Pages
- 312-316
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W2018025671
- Cited by
- 116
- References
- 24
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 3 · 2023: 7 · 2022: 3 · 2021: 10 · 2020: 6 · 2019: 4 · 2018: 18 · 2017: 4 · 2016: 10 · 2015: 12 · 2014: 9 · 2013: 7 · 2012: 9
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- interferon-beta, multiple sclerosis, severe depression, suicide attempts, suicidal ideation, adverse drug reactions, interferon withdrawal, Naranjo algorithm, psychiatric adverse effects
- MeSH terms
- Adult, Brazil, Depressive Disorder, Female, Humans, Interferon Type I, Male, Middle Aged, Multiple Sclerosis, Recombinant Proteins, Suicide, Attempted, Prevalence, Treatment Outcome, Drug Monitoring, Mood Disorders, Young Adult, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
